



US008846628B2

(12) **United States Patent**
Etter et al.

(10) **Patent No.:** **US 8,846,628 B2**
(45) **Date of Patent:** **Sep. 30, 2014**

(54) **ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF**

(75) Inventors: **Jeffrey B. Etter**, Boulder, CO (US); **Mei Lai**, Longmont, CO (US); **Jay Thomas Backstrom**, Leawood, KS (US)

(73) Assignee: **Celgene Corporation**, Summit, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 260 days.

(21) Appl. No.: **12/466,213**

(22) Filed: **May 14, 2009**

(65) **Prior Publication Data**

US 2009/0286752 A1 Nov. 19, 2009

Related U.S. Application Data

(60) Provisional application No. 61/053,609, filed on May 15, 2008, provisional application No. 61/157,875, filed on Mar. 5, 2009, provisional application No. 61/201,145, filed on Dec. 5, 2008.

(51) **Int. Cl.**

A01N 43/04 (2006.01)
A61K 31/70 (2006.01)
C07H 19/12 (2006.01)
A61K 9/28 (2006.01)
A61K 9/20 (2006.01)
A61K 31/706 (2006.01)
A61K 31/7068 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 9/2013** (2013.01); **A61K 9/2846** (2013.01); **A61K 9/2886** (2013.01); **A61K 31/706** (2013.01); **A61K 31/7068** (2013.01); **A61K 9/2018** (2013.01)

USPC **514/43**; 536/28.3

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,350,388 A 10/1967 Sorm et al.
3,817,980 A 6/1974 Vorbruggen et al.
3,891,623 A 6/1975 Vorbruggen et al.
4,082,911 A 4/1978 Vorbruggen
4,209,613 A 6/1980 Vorbruggen
5,700,640 A 12/1997 Voss et al.
6,432,924 B1 8/2002 Nyce
6,642,206 B2 11/2003 Ramasamy et al.
6,887,855 B2 5/2005 Ionescu et al.
6,890,547 B1 5/2005 Takada et al.
6,943,249 B2 9/2005 Ionescu et al.
7,038,038 B2 5/2006 Ionescu et al.
7,078,518 B2 7/2006 Ionescu et al.
7,189,740 B2 * 3/2007 Zeldis 514/323
7,192,781 B2 3/2007 Luna et al.
7,642,247 B2 1/2010 Daifuku et al.
7,700,770 B2 4/2010 Ionescu et al.

7,759,481 B2 7/2010 Gevenda et al.
7,772,199 B2 8/2010 Ionescu et al.
7,858,774 B2 12/2010 Ionescu et al.
8,058,424 B2 11/2011 Ionescu et al.
8,211,862 B2 7/2012 Ionescu et al.
2001/0026807 A1 10/2001 Watts
2002/0051820 A1 5/2002 Shell et al.
2003/0039688 A1 2/2003 Shell et al.
2003/0049311 A1 3/2003 McAllister et al.
2003/0104053 A1 6/2003 Gusler et al.
2003/0104062 A1 6/2003 Berner et al.
2003/0220254 A1 11/2003 Khan et al.
2004/0162263 A1 8/2004 Sands et al.
2005/0272675 A1 12/2005 Ionescu et al.
2006/0063735 A1 3/2006 Redkar et al.
2006/0069060 A1 3/2006 Redkar et al.
2006/0074046 A1 * 4/2006 Redkar et al. 514/49
2006/0128654 A1 6/2006 Tang et al.
2006/0247189 A1 11/2006 Ionescu et al.
2007/0190022 A1 * 8/2007 Bacopoulos et al. 424/85.1
2007/0270374 A1 11/2007 Gallop
2008/0057086 A1 3/2008 Etter et al.
2008/0182806 A1 7/2008 Pizzorno
2009/0286752 A1 11/2009 Etter et al.
2010/0035354 A1 2/2010 Bigatti et al.
2010/0036112 A1 2/2010 Henschke et al.
2010/0062992 A1 3/2010 Redkar et al.
2010/0210833 A1 8/2010 Jungmann et al.
2010/0292180 A1 11/2010 Ionescu et al.
2010/0298253 A1 11/2010 Ionescu et al.
2010/0311683 A1 12/2010 Beach et al.
2011/0042247 A1 2/2011 Kocherlakota et al.
2011/0092694 A1 4/2011 Ionescu et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CZ 114716 11/1964
CZ 116297 4/1965

(Continued)

OTHER PUBLICATIONS

(R) Dintaman et al., "Inhibition of P-Glycoprotein by D-[alpha]-Tocopherol Polyethylene Glycol 1000 Succinate," Pharmaceutical Research, 16(10), 1550-1556 (1999).*

(Continued)

Primary Examiner — Lawrence E Crane

(74) Attorney, Agent, or Firm — Jones Day

(57) **ABSTRACT**

The present disclosure provides pharmaceutical compositions comprising cytidine analogs, for example, 5-azacytidine or decitabine, for oral administration, wherein the compositions release the cytidine analog, for example, 5-azacytidine or decitabine, substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.

43 Claims, 23 Drawing Sheets

(56)

References Cited

U.S. PATENT DOCUMENTS

2011/0201800 A1 8/2011 Cherukupally et al.
 2011/0245485 A1 10/2011 De Ferra et al.
 2012/0196823 A1 8/2012 Tutino et al.
 2013/0109644 A1 5/2013 MacBeth et al.

FOREIGN PATENT DOCUMENTS

FR	2123632	9/1972
GB	1227691	4/1971
GB	1227692	4/1971
WO	WO 2004/082619	9/2004
WO	WO 2004/082822	9/2004
WO	WO 2006/034154	3/2006
WO	WO 2006/089290	8/2006
WO	WO 2008/028193	3/2008
WO	WO 2008/088779	7/2008
WO	WO 2009/016617	2/2009
WO	WO 2009/052287	4/2009
WO	WO 2009/139888	11/2009
WO	WO 2010/059969	5/2010
WO	WO 2011/014541	2/2011
WO	WO 2012/135405	10/2012
WO	WO 2013/022872	2/2013

OTHER PUBLICATIONS

- (S) Beers et al. (eds.), Chapter 142, Section 11, in *The Merck Manual of Diagnosis and Therapy*, 18th Edition, Merck & Co., Inc., Rahway, NJ, Jan. 2006, only title pages and text pp. 1114-1116 supplied.*
- (T) O'Neil et al. (eds.), "The Merck Index, 14th Edition," Merck & Co., Whitehouse Station, NJ, 2006, only title pages and p. 150 supplied (see Entry 890, "Azacitidine").*
- (U) Silverman et al., "Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B," *Journal of Clinical Oncology*, 20(10), 2429-2440 (May 15, 2002).*
- Aparicio et al., *Current Opinion in Investigational Drugs*, 2002, 3(4), 627-33.
- Argemi et al., *Journal of Pharmaceutical and Biomedical Analysis*, 2007, 44, 859-66.
- Beisler et al., *Journal of Medicinal Chemistry*, 1977, 20(6), 806-12.
- Bellet et al., *Cancer Chemotherapy Reports, Part I*, 1974, 58(2), 217-22.
- Bellet et al., *Medical and Pediatric Oncology*, 1978, 4, 11-15.
- Bhuyan et al., *Cancer Research*, 1972, 32, 398-407.
- Bhuyan et al., *Cancer Research*, 1973, 33, 888-94.
- Brock et al., *New England Journal of Medicine*, 2008, 358(11), 1118-28.
- Chan et al., *Journal of Pharmaceutical Sciences*, 1979, 68(7), 807-12.
- Christman et al., *Oncogene*, 2002, 21, 5483-95.
- Cunningham et al., *Cancer Chemotherapy Reports, Part I*, 1974, 58(5), 677-81.
- Curt et al., *Cancer Research*, 1985, 45, 3359-63.
- Das et al., *Molecular Cancer*, 2006, 5(28), doi: 10.1186/1476-4598-5-28, available at <http://www.molecular-cancer.com/content/5/1/28>.
- Dover et al., *Blood*, 1985, 66(3), 527-32.
- Fenaux et al., *The Lancet Oncology*, 2009, 10(3), 223-32.
- Garcia-Manero et al., *Current Opinion in Oncology*, 2008, 20, 705-10.
- Gifford et al., *Clinical Cancer Research*, 2004, 10, 4420-26.
- Israilli et al., *Cancer Research*, 1976, 36, 1453-61.
- Jordan et al., *New England Journal of Medicine*, 2006, 355(12), 1253-61.
- Jubb, et al., *Journal of Pathology*, 2001, 195, 111-34.
- Kornblith et al., *Journal of Clinical Oncology*, 2002, 20(10), 2441-52.
- Li et al., *Cancer Research*, 1970, 30, 2770-75.
- Lin et al., *Journal of Pharmaceutical Sciences*, 1981, 70(11), 1228-32.
- Lomen et al., *Cancer Chemotherapy Reports, Part I*, 1975, 59(6), 1123-26.
- Moertel et al., *Cancer Chemotherapy Reports, Part I*, 1972, 56(5), 649-52.
- Mojaverian et al., *Journal of Pharmacy and Pharmacology*, 1984, 36, 728-33.
- Neil, et al., *Cancer Chemotherapy Reports, Part I*, 1975, 59(3), 459-65.
- Notari et al., *Journal of Pharmaceutical Sciences*, 1975, 64(7), 1148-57.
- Quagliana et al., *Cancer Treatment Reports*, 1977, 61(1), 51-54.
- Sanderson et al., *Nature News*, Mar. 16, 2009, available at <http://www.nature.com/news/2009/090316/full/458269a.html>.
- Shnider et al., *Journal of Clinical Pharmacology*, 1976, 205-12.
- Silverman et al., *Journal of Clinical Oncology*, 2002, 20(10), 2429-40.
- Silverman et al., *Journal of Clinical Oncology*, 2006, 24(24), 3895-3903.
- Skikne et al., "A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)," *Journal of Clinical Oncology* (May 20, 2008 Supplement), 2008 ASCO Annual Meeting Proceedings (Meeting Date: May 30-Jun. 3, 2008), Part I, 2008, 26(15S), poster # 7091.
- Srinivasan et al., *American Journal of Clinical Oncology*, 1982, 5, 411-15.
- Stoltz et al., "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability," *Blood*, 48th ASH Annual Meeting (Meeting Date: Dec. 9-12, 2006), 2006, 108, poster # 4850.
- Tan et al., "Clinical Trial of 5-Azacitidine (5-azaCR)," *American Association for Cancer Research*, 64th Annual Meeting, Abstract # 385, Apr. 11-13, 1973.
- Troetel, et al., *Cancer Chemotherapy Reports, Part I*, 1972, 56(3), 405-11.
- Velez-Garcia et al., *Cancer Treatment Reports*, 1977, 61(9), 1675-77.
- Ward et al., "An Oral Dosage Formulation of Azacitidine: A Pilot Pharmacokinetic Study," *Journal of Clinical Oncology* (Jun. 20, 2007 Supplement), 2007 ASCO Annual Meeting Proceedings (Meeting Date: Jun. 1-5, 2007), Part I, 2007, 25(18S), poster # 7084.
- International Search Report, for PCT/US2009/002999, filed May 14, 2009.
- U.S. Appl. No. 13/273,127, filed Oct. 13, 2011, Ionescu et al.
- Beisler et al., "Chemistry of Antitumor Triazine Nucleosides. An Improved Synthesis of Dihydro-5-Azacitidine," *J. Carbohydrates Nucleosides Nucleotides*, 4(5): 281-99 (1977).
- Beisler, "Isolation, Characterization, and Properties of a Labile Hydrolysis Product of the Antitumor Nucleoside, 5-Azacitidine," *J. Med. Chem.*, 21(2): 204-08 (1978).
- Bergy et al., "Microbiological Production of 5-Azacitidine II. Isolation and Chemical Structure," *Antimicrobial Agents and Chemotherapy*, 625-30 (1966).
- Chen et al., "Highly Efficient Regioselective Synthesis of 5'-O-lauroyl-5-azacitidine Catalyzed by *Candida antarctica* Lipase B," *Appl. Biochem. Biotechnol.*, 151: 21-28 (2008).
- Garcia-Manero et al., "A Pilot Pharmacokinetic Study of Oral Azacitidine," *Leukemia*, 22: 1680-84 (2008).
- Garcia-Manero et al., "Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia," *J. Clin. Oncol.*, 29(18): 2521-27 (2011).
- Gaubert et al., "Unnatural Enantiomers of 5-Azacitidine Analogues: Synthesis and Enzymatic Properties," *Nucleosides, Nucleotides & Nucleic Acids*, 20(4-7): 837-40 (2001).
- Gut et al., "Aza Analogs of Pyrimidine and Purine Bases of Nucleic Acids," in *Advances in Heterocyclic Chemistry*, vol. 1, Katritzky ed., pp. 189-251 (1963).
- Hanka et al., "Microbiological Production of 5-Azacitidine I. Production and Biological Activity," *Antimicrobial Agents and Chemotherapy*, 619-24 (1966).
- Kritz et al., "Pilot Study of 5-Azacitidine (5-AZA) and Carboplatin (CBDCA) in Patients with Relapsed/Refractory Leukemia," *American Journal of Hematology*, 51(2): 117-21 (1996).

(56)

References Cited

OTHER PUBLICATIONS

Niedballa et al., "A General Synthesis of N-Glycosides. V. Synthesis of 5-Azacytidines," *J. Org. Chem.*, 39(25): 3672-74 (1974).
 Notice of Allowance dated Sep. 20, 2011 in U.S. Appl. No. 12/729,116.
 O'Neil et al. (eds.), *The Merck Index*. 13th Edition. p. 154-155 (2001).
 Office Action dated Sep. 23, 2011 in U.S. Appl. No. 12/787,214.
 Office Action dated Nov. 28, 2011 in U.S. Appl. No. 12/729,116.
 Piskala et al., "Nucleic Acids Components and Their Analogues. LI. Synthesis of 1-Glycosyl Derivatives of 5-Azauracil and 5-Azacytosine," *Collect. Czech. Chem. Commun.*, 29: 2060-76 (1964).
 Piskala et al., "Direct Synthesis of 5-Azapyrimidine Ribonucleosides," *Nucleic Acids Research*, Special Pub. No. 1: s17-20 (1975).
 Piskala et al., "Direct Synthesis of a 5-Azapyrimidine Ribonucleoside by the Tri-methylsilyl Procedure," *Nucleic Acid Chem.*, 1: 435-41 (1978).
 Vogler et al., "5-Azacytidine (NSC 102816): A New Drug for the Treatment of Myeloblastic Leukemia," *Blood*, 48(3): 331-37 (1976).
 Vorbruggen et al., "Nucleoside Synthesis with Trimethylsilyl Triflate and Perchlorate as Catalysts," *Chem. Ber.*, 114: 1234-55 (1981).
 Vorbruggen et al., "A New Simplified Nucleoside Synthesis," *Chem. Ber.*, 114: 1279-86 (1981).
 Vorbruggen et al., in *Organic Reactions*. vol. 55, 100 (L.A. Paquette ed., John Wiley & Sons, New York, 2000).
 Winkley et al., "Direct Glycosylation of 1,3,5-Triazinones. A New Approach to the Synthesis of the Nucleoside Antibiotic 5-Azacytidine (4-Amino-1- β -D-ribofuranosyl-1,3,5-triazin-2-one) and Related Derivatives," *J. Org. Chem.*, 35(2): 491-95 (1970).
 Wittenburg et al., "A New Synthesis of Nucleosides," *Zeitschrift fur Chemie*, 4: 303-04 (1964) (with English translation).
 Zaitseva et al., "Convergent Syntheses and Cytostatic Properties of 2-Chloro-2'-Deoxy-2'-Fluoroadenosine and its N⁷-Isomer," *Bioorg. & Med. Chem. Lett.*, 5(24): 2999-3002 (1995).
 Ziembra et al., "Development of Oral Demethylating Agents for the Treatment of Myelodysplastic Syndromes," *American Association of Cancer Research*, 100th Annual Meeting, Apr. 18-22, Abstract #3369 (2009).
 Notice of Allowability in U.S. Appl. No. 12/729,116, mailed May 4, 2012.
 Anonymous, "A Phase I/II Clinical Trial of Vidaza with Abraxane in the Treatment of Patients with Advanced or Metastatic Solid Tumors

and Breast Cancer," *ClinicalTrials.gov* archive, pp. 1-3, retrieved from the Internet: http://clinicaltrials.gov/archive/NCT00748553/2011_08_05, on Jan. 31, 2013.

Anonymous, "Oral Azacitidine as a Single Agent and in Combination with Carboplatin or Abraxane in Subjects with Relapsed or Refractory Solid Tumors," *ClinicalTrials.gov* archive, pp. 1-4, retrieved from the Internet: http://clinicaltrials.gov/archive/NCT01478685/2011_11_22, on Jan. 31, 2013.

Bast et al., "A Phase IIa Study of a Sequential Regimen Using Azacitidine to Reverse Platinum Resistance to Carboplatin in Patients with Platinum Resistant or Refractory Epithelial Ovarian Cancer," *Journal of Clinical Oncology*, 26, Abstract 3500, (2008).

Cowan et al., "Will DNA Methylation Inhibitors Work in Solid Tumors? A Review of the Clinical Experience with Azacitidine and Decitabine in Solid Tumors," *Epigenomics, Future Medicine Ltd, United Kingdom*, 2(1):71-86 (2010).

Glaser, "HDAC Inhibitors: Clinical Update and Mechanism-Based Potential," *Biochem. Pharm.*, 74:659-71 (2007).

Howell et al., "Demethylating Agents in the Treatment of Cancer," *Pharmaceuticals*, 3(7):202-44 (2010).

Juergens et al., "Interim Analysis of a Phase II Trial of 5-Azacitidine (5AC) and Entinostat (SNDX-275) in Relapsed Advanced Lung Cancer (NSCLC)," *Journal of Clinical Oncology*, 27(15S):8055 (2009).
 Momparler, "Epigenetic Therapy of Cancer with 5-Aza-2'-Deoxycytidine (Decitabine)," *Seminars in Oncology*, 32(5):443-51 (2005).

Stathis et al., "Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas," *Clinical Cancer Research*, 17(6):1582-90 (2011).

VidazaTM Label (azacitidine for injectable suspension), Version: May 18, 2004.

VidazaTM (azacitidine for injection) Prescribing Information, dated Jan. 2012.

Garcia-Manero et al., "Safety and efficacy of oral azacitidine (CC-486) administered in extended treatment schedules to patients with lower-risk myelodysplastic syndromes," *Blood*, 120:Abstract 424 (2012).

Garcia-Manero et al., "Phase I study; of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia," *J. Clin. Oncol.*, 29:2521-2527 (2011).

VidazaTM (azacitidine for injection) Prescribing Information, dated Dec. 2012.

* cited by examiner




FIG. 1




FIG.2

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.